Metabolic dysfunction associated fatty liver disease, MAFLD
Conditions
Interventions
Treatment group:Lifestyle Guidance + Caffeic Acid Tablets
Sponsors
Huadong Hospital Affiliated to Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-65 years; 2. BMI: 23-30 kg/m^2; 3. Pathological diagnosis of liver biopsy or clinical compliance with MAFLD within the past 20 weeks; 4. Undiagnosed diabetes; 5. Agree and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Excessive drinkers (definition: in the past 6 months, the weekly alcohol intake exceeds 140g for men and more than 70g for women); 2. Liver enzymes (ALT or AST) >= 5 times the upper limit of normal; 3. Liver diseases caused by other causes: such as alcoholic liver disease, acute and chronic viral hepatitis, drug-induced, autoimmune liver disease, hereditary liver disease, liver cirrhosis, liver cancer, etc.; 4. Biliary diseases: biliary obstructive diseases, etc.; 5. Other diseases affecting glucose and lipid metabolism: hyperthyroidism, hypothyroidism, hypercortisolism, etc.; 6. Use of drugs that may affect the endpoints of this study within the first three months of enrollment, including pioglitazone, GLP-1 receptor agonists, DDP-4 inhibitors, insulin, and glycyrrhizic acid preparations; 7. Chronic kidney disease or severe renal impairment, defined as serum creatinine greater than 176.8umol/L; 8. The life expectancy is not more than 5 years; 9. Those who are pregnant or plan to become pregnant within the next 1 year; 10. Those who are expected to be unable to complete the intervention follow-up in other circumstances; 11. Continued use of drugs that may affect steatohepatitis for more than 2 weeks (such as cortisol, methotrexate, etc.) within the first three months of enrollment; 12. Participated in other clinical trials within the past 4 weeks; 13. The researcher believes that it is not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| controlled attenuation parameters (CAP); | — |
Secondary
| Measure | Time frame |
|---|---|
| liver function test;fasting blood glucose;blood lipid;insulin;human body index (height, weight, waist circumference);liver stiffness measurement;high-sensitivity C-reactive protein; | — |
Countries
China
Contacts
Public ContactChen Yuanwen
Huadong Hospital Affiliated to Fudan University
Outcome results
None listed